Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 37


Compositional Features of HDL Particles Interact with Albuminuria to Modulate Cardiovascular Disease Risk.

Corsetti JP, Bakker SJL, Gansevoort RT, Gruppen EG, Connelly MA, Sparks CE, Dullaart RPF.

Int J Mol Sci. 2019 Feb 23;20(4). pii: E977. doi: 10.3390/ijms20040977.


Pooled Analysis of Multiple Crossover Trials To Optimize Individual Therapy Response to Renin-Angiotensin-Aldosterone System Intervention.

Petrykiv SI, Laverman GD, Persson F, Vogt L, Rossing P, de Borst MH, Gansevoort RT, de Zeeuw D, Heerspink HJL.

Clin J Am Soc Nephrol. 2017 Nov 7;12(11):1804-1813. doi: 10.2215/CJN.00390117. Epub 2017 Oct 11. Review.


Urinary renin-angiotensin markers in polycystic kidney disease.

Salih M, Bovée DM, Roksnoer LCW, Casteleijn NF, Bakker SJL, Gansevoort RT, Zietse R, Danser AHJ, Hoorn EJ.

Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F874-F881. doi: 10.1152/ajprenal.00209.2017. Epub 2017 Jul 26.


Cardiovascular outcome trials in patients with chronic kidney disease: challenges associated with selection of patients and endpoints.

Rossignol P, Agarwal R, Canaud B, Charney A, Chatellier G, Craig JC, Cushman WC, Gansevoort RT, Fellström B, Garza D, Guzman N, Holtkamp FA, London GM, Massy ZA, Mebazaa A, Mol PGM, Pfeffer MA, Rosenberg Y, Ruilope LM, Seltzer J, Shah AM, Shah S, Singh B, Stefánsson BV, Stockbridge N, Stough WG, Thygesen K, Walsh M, Wanner C, Warnock DG, Wilcox CS, Wittes J, Pitt B, Thompson A, Zannad F.

Eur Heart J. 2019 Mar 14;40(11):880-886. doi: 10.1093/eurheartj/ehx209.


Effect of Tolvaptan in Autosomal Dominant Polycystic Kidney Disease by CKD Stage: Results from the TEMPO 3:4 Trial.

Torres VE, Higashihara E, Devuyst O, Chapman AB, Gansevoort RT, Grantham JJ, Perrone RD, Ouyang J, Blais JD, Czerwiec FS; TEMPO 3:4 Trial Investigators.

Clin J Am Soc Nephrol. 2016 May 6;11(5):803-11. doi: 10.2215/CJN.06300615. Epub 2016 Feb 23.


Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: The PREVEND study.

Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Blokzijl H, Gansevoort RT, Dullaart RP.

Atherosclerosis. 2015 Nov;243(1):138-47. doi: 10.1016/j.atherosclerosis.2015.09.006. Epub 2015 Sep 8.


Serum Alkaline Phosphatase and Risk of Incident Cardiovascular Disease: Interrelationship with High Sensitivity C-Reactive Protein.

Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Gregson J, Dullaart RP.

PLoS One. 2015 Jul 13;10(7):e0132822. doi: 10.1371/journal.pone.0132822. eCollection 2015.


Added value of screening for CKD among the elderly or persons with low socioeconomic status.

Vart P, Reijneveld SA, Bültmann U, Gansevoort RT.

Clin J Am Soc Nephrol. 2015 Apr 7;10(4):562-70. doi: 10.2215/CJN.09030914. Epub 2015 Mar 16.


Circulating total bilirubin and risk of incident cardiovascular disease in the general population.

Kunutsor SK, Bakker SJ, Gansevoort RT, Chowdhury R, Dullaart RP.

Arterioscler Thromb Vasc Biol. 2015 Mar;35(3):716-24. doi: 10.1161/ATVBAHA.114.304929. Epub 2015 Jan 15. Review.


Circulating gamma glutamyltransferase and prediction of cardiovascular disease.

Kunutsor SK, Bakker SJ, Kootstra-Ros JE, Gansevoort RT, Dullaart RP.

Atherosclerosis. 2015 Feb;238(2):356-64. doi: 10.1016/j.atherosclerosis.2014.12.045. Epub 2014 Dec 23.


Twenty-four hour urinary urea excretion and 9-year risk of hypertension: the PREVEND study.

Tielemans SM, Geleijnse JM, van Baak MA, Engberink MF, Brink EJ, de Jong PE, Gansevoort RT, Bakker SJ; PREVEND Study Group.

J Hypertens. 2013 Aug;31(8):1564-9. doi: 10.1097/HJH.0b013e328362213b.


Urinary vitamin D binding protein: a potential novel marker of renal interstitial inflammation and fibrosis.

Mirković K, Doorenbos CR, Dam WA, Lambers Heerspink HJ, Slagman MC, Nauta FL, Kramer AB, Gansevoort RT, van den Born J, Navis G, de Borst MH.

PLoS One. 2013;8(2):e55887. doi: 10.1371/journal.pone.0055887. Epub 2013 Feb 11.


Screening for chronic kidney disease can be of help to prevent atherosclerotic end-organ damage.

Özyilmaz A, de Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2012 Nov;27(11):4046-52. doi: 10.1093/ndt/gfs438. Review.


Influence of urine creatinine on the relationship between the albumin-to-creatinine ratio and cardiovascular events.

Carter CE, Gansevoort RT, Scheven L, Heerspink HJ, Shlipak MG, de Jong PE, Ix JH.

Clin J Am Soc Nephrol. 2012 Apr;7(4):595-603. doi: 10.2215/CJN.09300911. Epub 2012 Mar 1.


Do albuminuria and hs-CRP add to the International Diabetes Federation definition of the metabolic syndrome in predicting outcome?

van der Velde M, Bello AK, Brantsma AH, El Nahas M, Bakker SJ, de Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2012 Jun;27(6):2275-83. doi: 10.1093/ndt/gfr634. Epub 2012 Jan 9.


Development and validation of a general population renal risk score.

Halbesma N, Jansen DF, Heymans MW, Stolk RP, de Jong PE, Gansevoort RT; PREVEND Study Group.

Clin J Am Soc Nephrol. 2011 Jul;6(7):1731-8. doi: 10.2215/CJN.08590910.


Selection on albuminuria enhances the efficacy of screening for cardiovascular risk factors.

Özyilmaz A, Bakker SJ, de Zeeuw D, de Jong PE, Gansevoort RT; PREVEND Study Group.

Nephrol Dial Transplant. 2010 Nov;25(11):3560-8. doi: 10.1093/ndt/gfq478. Epub 2010 Aug 11.


Comparison of the yield of different screening approaches to detect chronic kidney disease.

van der Velde M, de Jong PE, Gansevoort RT.

Nephrol Dial Transplant. 2010 Oct;25(10):3222-30. doi: 10.1093/ndt/gfq156. Epub 2010 Mar 24.


Changes in renal risk factors versus renal function outcome during follow-up in a population-based cohort study.

Halbesma N, Jansen DF, Stolk RP, De Jong PE, Gansevoort RT; PREVEND Study group.

Nephrol Dial Transplant. 2010 Jun;25(6):1846-53. doi: 10.1093/ndt/gfp729. Epub 2010 Jan 6.


High protein intake associates with cardiovascular events but not with loss of renal function.

Halbesma N, Bakker SJ, Jansen DF, Stolk RP, De Zeeuw D, De Jong PE, Gansevoort RT; PREVEND Study Group.

J Am Soc Nephrol. 2009 Aug;20(8):1797-804. doi: 10.1681/ASN.2008060649. Epub 2009 May 14.

Supplemental Content

Loading ...
Support Center